Unnamed programs
Traumatic Brain Injury (TBI)
Key Facts
About Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is a private, clinical-stage biotechnology company focused on harnessing the therapeutic potential of astrocytes and other glial cells to treat brain injuries and neurodegenerative disorders. The company has achieved significant milestones including FDA clearance of an IND for AST-004, initiation of a Phase 2 clinical trial for concussion, and securing multiple NIH grants and financing rounds totaling over $9M. With a strong scientific foundation and experienced leadership team, Astrocyte is positioned to advance a new class of cerebroprotective therapies for conditions with high unmet medical need.
View full company profileAbout Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals is a private, clinical-stage biotechnology company focused on harnessing the therapeutic potential of astrocytes and other glial cells to treat brain injuries and neurodegenerative disorders. The company has achieved significant milestones including FDA clearance of an IND for AST-004, initiation of a Phase 2 clinical trial for concussion, and securing multiple NIH grants and financing rounds totaling over $9M. With a strong scientific foundation and experienced leadership team, Astrocyte is positioned to advance a new class of cerebroprotective therapies for conditions with high unmet medical need.
View full company profileTherapeutic Areas
Other Traumatic Brain Injury (TBI) Drugs
| Drug | Company | Phase |
|---|---|---|
| CEVA-101 (pediatric & adult) | Fortress Biotech | Phase 2 |
| CEVA-102 | Fortress Biotech | Preclinical |